Gemtuzumab ozogamicin is a drug-linked monoclonal antibody (an antibody-
drug conjugate) that was used to treat acute myelogenous leukemia from 2000 to
Jun 24, 2010 ... Pfizer, Inc., in agreement with the FDA, announced their discontinuing
commercial marketing of gemtuzumab ozogamicin (Mylotarg) as of ...
Mylotarg is the trade name for gemtuzumab ozogamicin. In some cases, health
care professionals may use the trade name mylotarg when referring to the ...
Information about the monoclonal antibody gemtuzumab (Mylotarg®), which is
mainly used as part of research trials to treat some types of acute myeloid ...
Jul 19, 2015 ... Gemtuzumab ozogamicin (Mylotarg®; Pfizer/Wyeth-Ayerst Laboratories) is a
recombinant, humanized anti-CD33 monoclonal antibody (IgG4 κ ...
Gemtuzumab ozogamicin (GO) consists of a humanized anti-CD33 monoclonal
antibody conjugated with calicheamicin, a potent antitumor anthracycline ...
BACKGROUND: Gemtuzumab ozogamicin (GO) is an immunoconjugate
consisting of the CD33 antibody and calicheamicin, a potent cytotoxic agent.
Mylotarg® (gemtuzumab ozogamicin for Injection) is a chemotherapy agent
composed of a recombinant humanized IgG4, kappa antibody conjugated with a
On May 17, 2000, the US Food and Drug Administration (FDA) granted
accelerated approval for the use of gemtuzumab ozogamicin (GO) in older
patients (age ...
Mylotarg (gemtuzumab ozogamicin): Market Withdrawal. Audience: Oncology,
Hematology. [Posted 06/21/2010]. ISSUE: FDA notified healthcare professionals